BGI Signs Memorandum of Understanding with VPC
News May 20, 2016
BGI and Vancouver Prostate Centre (VPC) have signed a memorandum of understanding to bring together advanced and cost effective sequencing, genomics and computing technologies of BGI with the world class translational cancer research and drug development program at the VPC. The BGI-VPC Joint Research Laboratory will also work to advance individualized therapy for cancer through evidence-based precision oncology and carry out clinical trials and commercialization for treatment of prostate and others cancers.
The MoU was signed at a signing ceremony at the Vancouver Convention Centre as part of the official visit of Guangdong Provence’s Party Secretary Hu Chunhua to British Columbia. The agreement was witnessed by the Honourable Christy Clark, Premier of British Columbia and researchers Dr. Colin Collins and Dr. Yuzhuo Wang of the Vancouver Prostate Centre. At the VPC, doctors and scientists work together closely seeking better outcomes for patients with prostate and other cancers. To do this, they are constantly creating and studying new drugs.
“The Vancouver Prostate Centre has world leading capabilities in discovering novel cancer gene targets and developing first in field drugs to better treat advanced cancer,” said Dr. Martin Gleave, Executive Director, Vancouver Prostate Centre, Distinguished Professor and Head of Department of Urologic Sciences, UBC. BGI is the largest genome organization in the world and the VPC is a world leading translational prostate cancer centre with a very large tissue bank including a unique living tumour bank, a large patient population, and an efficient discovery and translation pipeline.
Together BGI and the VPC have an opportunity to combine their complementary strengths to focus on and accelerate translational oncology and personalized medicine. Over the past two years BGI and VPC scientists and clinicians have combined clinical expertise, a unique repository of metastatic and post-treated cancer specimens, and cutting edge genomics with the goal of improving patient outcomes and quality of life through development of targeted therapies and ultimately evidence based precision oncology. A specific example includes the development of non invasive “liquid biopsies” for monitoring men with advanced metastatic prostate cancer.
“One of our dedicated efforts is to develop precision medicine towards more effective treatments to patients,” said Dr. Jian Wang, President of BGI. “This agreement will bridge research and training from the best researchers in British Columbia and China to share expertise in meeting our goal to control prostate and other cancers,” said Dr. Colin Collins, Director of BGI-VPC Joint Research Laboratory and Professor in the Department of Urologic Sciences at UBC and at BGI.
Added Dr. Yuzhuo Wang Professor at UBC, Co-Director of the BGI-VPC Joint Research Laboratory and founder of the Living Tumor Laboratory, “this partnership will also capitalize on world leading ability to propagate patient derived tumours as avatars- the key missing link in ‘evidence-based’ precision oncology.” The Vancouver Prostate Centre (VPC) is a UBC and VGH Centre of Excellence and a National Centre of Excellence for Commercialization and Research (CECR). The Centre’s research focuses on the discovery of molecular mechanisms of cancer progression, therapeutic resistance, and the development of new treatments, services, and products to improve outcomes in patients with cancer.
The VPC comprises a multi-disciplinary team of 23 senior research and clinical scientists and more than 200 staff in three facilities. The VPC integrates the expertise of scientists and clinicians in urology, cellular and molecular biology, pharmacology, socio-behavioural sciences, functional genomics, and medical oncology.
Cryo-EM Reveals Interaction Between Major Drug TargetsNews
For the first time, scientists have visualized the interaction between two critical components of the body's vast cellular communication network, a discovery that could lead to more effective medications with fewer side effects for conditions ranging from migraine to cancer.READ MORE
New Ovarian Cancer TargetNews
Researchers have found a prescription drug, Calcitriol, approved by the Food and Drug Administration for the treatment of calcium deficiency and kidney diseases, may increase the likelihood of surviving ovarian cancer. This new study opens a potential avenue for treating ovarian cancer. Since Calcitriol is an FDA-approved drug, no additional research is needed before the drug can advance to human clinical trials for ovarian cancer.READ MORE
Genetic Discovery Helps Determine the Difference Between Aggressive & Benign Bone TumorsNews
The first genetic marker for the bone tumor, osteoblastoma, has been discovered. Whole-genome and transcriptome sequencing of human bone tumors revealed that a genetic change that affects the transcription factor, FOS, is a hallmark mutation of osteoblastoma. The results will help clinicians correctly distinguish benign osteoblastoma tumors from aggressive osteosarcoma tumors and direct the correct treatment.READ MORE
Comments | 0 ADD COMMENT
International Conference on Central Nervous System and Therapeutics
Nov 12 - Nov 14, 2018